FORM PTO-1449/A and B (modified PTO/SB/08)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1	of	3

APPLICATION NO.: 10/565,021	ATTY. DOCKET NO.: G0762.70006US01
FILING DATE: January 17, 2006	CONFIRMATION NO.: 9002
APPLICANT: Schlegel et al.	
GROUP ART UNIT: Not Yet Assigned	EXAMINER: Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document Number	U.S. Patent Document Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
[signature]	A1	5,989,807		West et al.	11-23-1999

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document Office/ Country	Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
[signature]	B1	WO	99/29890	A2	Digene Corporation	06-17-1996	
	B2	WO	02/08764	A1	Medical Research Council	01-31-2002	
	B3	WO	02/078695	A1	Board of Regents, The University of Texas System	10-10-2002	
	B4	International Search Report and Written Opinion. International Application: PCT/US2004/023014. Mailing date: April 14, 2005.					
	B5	International Preliminary Report on Patentability. International Application: PCT/US2004/023014. Mailing date: February 2, 2006.					

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
[signature]	C1	ANDERSON et al., Telomerase activation in cervical cancer. Am J Pathol. 1997 Jul;151(1):25-31.	
	C2	BAEGE et al., Cervical epithelial cells transduced with the papillomavirus E6/E7 oncogenes maintain stable levels of oncoprotein expression but exhibit progressive, major increases in hTERT gene expression and telomerase activity. Am J Pathol. 2002 Apr;160(4):1251-7.	
	C3	BAEGE et al., IGFBP-3, a marker of cellular senescence, is overexpressed in human papillomavirus-immortalized cervical cells and enhances IGF-1-induced mitogenesis. J Virol. 2004 Jun;78(11):5720-7.	
	C4	BAXTER et al., Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog Growth Factor Res. 1989;1(1):49-68.	

EXAMINER: [signature]	DATE CONSIDERED: 7.6.07

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/565,021	ATTY. DOCKET NO.: G0762.70006US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: January 17, 2006	CONFIRMATION NO.: 9002
	APPLICANT: Schlegel et al.	
Sheet 2 of 3	GROUP ART UNIT: Not Yet Assigned	EXAMINER: Not Yet Assigned

	C5	BAXTER et al., Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000 Jun;278(6):E967-76.	
	C6	BAXTER et al., Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol. 2001 Jun;54(3):145-8.	
	C7	BERGER et al., Insulin-like growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins. Am J Pathol. 2002 Aug;161(2):603-10.	
	C8	BLACKWOOD et al., Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science. 1991 Mar 8;251(4998):1211-7.	
	C9	HENRIKSSON et al., Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene. 1993 Dec;8(12):3199-209.	
	C10	IMURA et al., Beta-catenin expression as a prognostic indicator in cervical adenocarcinoma. Int J Mol Med. 2001 Oct;8(4):353-8.	
	C11	KANG et al., Diagnose kit detect cervix cancer. Database WPI, XP002305239 & KR 2002 012 838. Biograng Co Ltd. February 20, 2002. Abstract.	
	C12	KELLEY et al., Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol. 1996 Jun;28(6):619-37.	
	C13	KIM et al., Specific association of human telomerase activity with immortal cells and cancer. Science. 1994 Dec 23;266(5193):2011-5.	
	C14	LLOYD et al., Demonstration of an epitope of the transferrin receptor in human cervical epithelium—a potentially useful cell marker. J Clin Pathol. 1984 Feb;37(2):131-5.	
	C15	MEYERSON et al., hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997 Aug 22;90(4):785-95.	
	C16	PEIFER et al., Beta-catenin as oncogene: the smoking gun. Science. 1997 Mar 21;275(5307):1752-3.	
	C17	RAMAKRISHNAN et al., Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res. 1998 Feb 15;58(4):622-5.	
	C18	RUBINFELD et al., Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science. 1997 Mar 21;275(5307):1790-2.	
	C19	SHINOHARA et al., Cytoplasmic/nuclear expression without mutation of exon 3 of the beta-catenin gene is frequent in the development of the neoplasm of the uterine cervix. Gynecol Oncol. 2001 Sep;82(3):450-5.	
	C20	TAKAKURA et al., Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res. 1998 Apr 1;58(7):1558-61.	
	C21	THOMAS et al., Human papillomavirus oncoproteins E6 and E7 independently abrogate the mitotic spindle checkpoint. J Virol. 1998 Feb;72(2):1131-7.	
	C22	ÜREN et al., Activation of the canonical Wnt pathway during genital keratinocyte transformation: a model for cervical cancer progression. Cancer Res. 2005 Jul 15;65(14):6199-206.	
	C23	VELDMAN et al., Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol. 2001 May;75(9):4467-72.	

EXAMINER:	DATE CONSIDERED: 7.6.07

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/565,021	ATTY. DOCKET NO.: G0762.70006US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: January 17, 2006	CONFIRMATION NO.: 9002
				APPLICANT: Schlegel et al.	
Sheet	3	of	3	GROUP ART UNIT: Not Yet Assigned	EXAMINER: Not Yet Assigned

	C24	VELDMAN et al., Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8211-6.	
	C25	YATABE et al., 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther. 2002 Jul;9(7):624-30.	
	C26	YUAN et al., Simian virus 40 small tumor antigen activates AKT and telomerase and induces anchorage-independent growth of human epithelial cells. J Virol. 2002 Nov;76(21):10685-91.	

•a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __ , filed __ , and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
	7.6.07

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

1064060.1